- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004380
Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
June 23, 2005 updated by: National Center for Research Resources (NCRR)
OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma).
II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.
Study Overview
Detailed Description
PROTOCOL OUTLINE: This is a compassionate use study.
The patient is treated with subcutaneous injections of recombinant relaxin for approximately 12 months.
If clinically indicated, therapy may be extended.
Study Type
Interventional
Enrollment
1
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Progressive systemic sclerosis (scleroderma)
- No pregnant or nursing women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: G. Scott Herron, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 1991
Study Completion
December 1, 1997
Study Registration Dates
First Submitted
October 18, 1999
First Submitted That Met QC Criteria
October 18, 1999
First Posted (Estimate)
October 19, 1999
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
July 1, 2004
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 199/12015
- SUMC-37488
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
W. Leroy GriffingRecruitingSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
-
Mitsubishi Tanabe Pharma America Inc.CompletedDiffuse Cutaneous Systemic SclerosisSpain, Belgium, United States, United Kingdom, Poland, Canada, Germany, Italy
Clinical Trials on relaxin
-
Novartis PharmaceuticalsCompleted
-
University of EdinburghNovartis Pharmaceuticals; NHS LothianCompleted
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...CompletedHeart Failure, CongestiveGermany
-
University of Medicine and Dentistry of New JerseyBoston University; Medical University of South Carolina; Johns Hopkins University and other collaboratorsCompletedSystemic Sclerosis
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...CompletedHeart Failure, CongestiveUnited States, Israel
-
D.O. Ott Research Institute of Obstetrics, Gynecology...CompletedInfertility | Reproductive Techniques, Assisted | Oocyte MaturationRussian Federation
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...Suspended
-
Cambridge University Hospitals NHS Foundation TrustAstraZeneca; University of Cambridge; MedImmune LLCActive, not recruitingCardiovascular Diseases | Type 2 Diabetes MellitusUnited Kingdom